$496 Million is the total value of Aquilo Capital Management, LLC's 14 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 0.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
PIRS | PIERIS PHARMACEUTICALS INC | $17,284,000 | +36.0% | 5,575,530 | 0.0% | 3.48% | -29.7% | |
PRQR | PROQR THRAPEUTICS N V | $14,602,000 | +10.7% | 2,401,570 | 0.0% | 2.94% | -42.7% | |
GLPG | GALAPAGOS NVspon adr | $8,727,000 | +0.7% | 44,234 | 0.0% | 1.76% | -47.9% | |
MOR | MORPHOSYS AGsponsored ads | $3,037,000 | +28.9% | 95,898 | 0.0% | 0.61% | -33.3% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-08-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
PIERIS PHARMACEUTICALS INC | 20 | Q3 2023 | 7.1% |
ARROWHEAD PHARMACEUTICALS INC | 18 | Q3 2023 | 22.1% |
UNIQURE NV | 18 | Q1 2023 | 10.8% |
SPERO THERAPEUTICS INC | 16 | Q3 2022 | 15.8% |
REGENXBIO INC | 16 | Q3 2023 | 12.6% |
BLUEPRINT MEDICINES CORP | 15 | Q3 2023 | 17.3% |
ARGENX SE | 15 | Q3 2023 | 3.7% |
SPDR S&P BIOTECH ETF TR | 14 | Q4 2022 | 52.1% |
MERUS N V | 14 | Q3 2023 | 13.0% |
GENMAB A/S | 13 | Q3 2023 | 3.9% |
View Aquilo Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
Spero Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
Merus N.V. | February 14, 2020 | 814,505 | 2.8% |
SYNLOGIC, INC.Sold out | February 14, 2020 | 0 | 0.0% |
View Aquilo Capital Management, LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
SC 13G | 2024-03-18 |
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-14 |
13F-HR | 2023-05-15 |
SC 13G/A | 2023-02-14 |
SC 13G/A | 2023-02-14 |
SC 13G/A | 2023-02-14 |
13F-HR | 2023-02-14 |
View Aquilo Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.